semaglutide cardiovascular outcomes news 2025 october #VisualAbstract: and in Obesity without Diabetes Cardiovascular outcomes of semaglutide and

Alternatives Although retatrutide is the new frontier in obesity management, there are still many effective, FDA-approved pharmaceutical options available to patients today, as well as important lifestyle foundations

Biochem Biophys Res Commun 188:10901096 Gebicke-Haerter PJ, Van Calker D, Norenberg W, Illes P (1996) Molecular mechanisms of microglial activation

Robotic PD was indicated for pancreatic head adenocarcinoma (N = 50, 46%), duodenal/ampullary tumor (N = 25, 23%), intraductal papillary mucinous neoplasm (N = 19, 18%) and a minority of pancreatic neuroendocrine tumor, cholangiocarcinoma, or other

Mental or Physical Fatigue Weekly injections and constant weight management can become emotionally exhausting

Even after adjusting for, PCOS remains an independent risk factor for hepatic steatosis and ( 2.3 GLP-1: from glucose-lowering strategy to a multi-system metabolic protection platform As a core incretin secreted by enteroendocrine L-cells, not only regulates insulin and glucagon secretion in a glucose-dependent manner but also serves as a central controller of energy homeostasis